Irvine, CA-The Cryocare CN2 System from Endocare, Inc. has received 510K clearance from the FDA. The device uses the freezing capability of nitrogen at the point between gas and liquid-"critical nitrogen"-to destroy cancerous tissue quicker and more cost-effectively than argon can, according to the manufacturer. The speed and precision of this new technology can expedite procedures, Endocare says, because it is easy to use and it delivers a colder, more powerful ice ball at the end of the probes.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
2 Clarke Drive
Cranbury, NJ 08512